BofA cuts Prothena stock rating, slashes target to $4

BofA Securities downgraded Prothena Corp (PRTA) from Neutral to Underperform, slashing the price target from $22 to $4 following the Phase 3 trial failure of its lead drug, birtamimab, for AL Amyloidosis. The failure led BofA to remove birtamimab from its valuation model, which previously contributed $15 per share to the price target. While Prothena is developing PRX012 for Alzheimer’s, BofA remains cautious, requiring clear differentiation from existing treatments before turning bullish, reflecting a broader trend of analysts adjusting ratings and price targets after the trial results.

Analysis

Prothena Corp. faces a significantly challenged outlook following BofA Securities' downgrade to Underperform and a drastic price target reduction from $22.00 to $4.00. This action was primarily driven by the failure of Prothena’s lead drug candidate, birtamimab, in a crucial phase 3 trial for AL Amyloidosis, leading BofA to remove the drug, previously valued at $15 per share, from its model. The company's stock, currently trading around $4.58, has plummeted nearly 77% over the past year and is near its 52-week low of $4.45, reflecting the severe market reaction to this clinical setback. While Prothena's pipeline includes PRX012, an early-stage monoclonal antibody for Alzheimer’s disease, BofA expresses significant caution, requiring clear signs of differentiation from existing therapies, particularly given the underwhelming performance of currently approved Alzheimer’s treatments. This skepticism is largely shared across Wall Street, with Oppenheimer, Jefferies, and Cantor Fitzgerald also issuing downgrades or cautious revisions, citing the birtamimab disappointment. However, Piper Sandler and H.C. Wainwright, despite substantial price target reductions to $81 (from $110) and $14 (from $30) respectively, maintained Overweight/Buy ratings, pinning hopes on PRX012's potential. Prothena's management has responded by announcing significant cost-cutting measures and a strategic focus on its Alzheimer's pipeline, with further updates anticipated later this year and into 2025. Despite an InvestingPro Fair Value analysis suggesting potential undervaluation for its $246.5 million market capitalization and a 'FAIR' overall Financial Health score, the recent trial failure has fundamentally altered the company's risk profile and future prospects.

Key Decisions for Investors

• Investors should exercise extreme caution due to the catastrophic Phase 3 trial failure of birtamimab, the subsequent sharp stock decline, and BofA Securities' aggressive price target cut to $4.00, which is below the current trading price.
• The company's valuation now hinges precariously on the success of its early-stage Alzheimer's candidate, PRX012; any investment thesis must carefully weigh the high-risk, high-reward nature of this asset and closely monitor upcoming clinical data for differentiation.
• Note the divergent analyst opinions: while BofA is strongly bearish, firms like Piper Sandler and H.C. Wainwright see speculative potential in PRX012, albeit with significantly lowered price targets, reflecting broad uncertainty.
• Monitor Prothena’s execution of planned cost-cutting measures and its strategy to preserve capital and advance PRX012, as financial runway will be critical following the major pipeline setback.